Unitaid audited financial report for the year ended 31 December 2021
Unitaid Strategy 2023-2027
Financial Guidelines for Unitaid Grant Implementers (Frequently Asked Questions)
Unitaid 2017-2021 Strategy Review, Management Response, Dec 2021
Unitaid 2017-2021 Strategy Review, Final Report, Vol 2, Annexes
Unitaid 2017-202 Strategy Review, Final Report, Vol 1, Main report
Multipurpose prevention technologies: Technology landscape and potential for low- and middle-income countries
Financial guidelines for Unitaid grant implementers
Unitaid’s climate and health strategy 2023-2027
Unitaid’s investment case 2023-2027, executive summary
Unitaid’s investment case 2023-2027
Unitaid Strategy 2023-2027
Maternal and newborn health
Women’s and children’s health
Building for sustainability: Accelerating regional manufacturing for diagnostics (FIND and Unitaid)
Meeting report: Strengthening cooperation to enable sustainable development and manufacturing of effective, quality and affordable diagnostic countermeasures (FIND and Unitaid)
Q&A: Monoclonal antibodies
From milligrams to megatons: A climate and nature assessment of 10 key health products
Executive summary: From milligrams to megatons: A climate and nature assessment of 10 key health products
Landscape of rapid diagnostic tests for severe bacterial infections in advanced HIV Disease
The health products manufacturers support platform: Enhancing regional manufacturing of health technologies in Africa
Novel business models for accessible monoclonal antibodies for infectious diseases in LMICS: Multistakeholder meeting recommendations
Unitaid and the Government of Spain
About Unitaid (Saving lives faster)
Unitaid and the UK Government
Unitaid audited financial report for the year ended 31 December 2023
Partnership report: Unitaid and the Global Fund to Fight AIDS, Tuberculosis and Malaria
Unitaid audited financial report for the year ended 31 December 2022
Key Performance Indicators 2009
Unitaid transparency policy
Policy on ethics and conflict of interest for Unitaid
